Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minehiko Inomata

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Cancer Diagnosis & Prognosis|May 9, 2022
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung CancerMinehiko Inomata, Masahiro Matsumoto, Isami Mizushima, et al.
Anticancer Research|June 23, 2023
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint InhibitorsMinehiko Inomata, Masahiro Matsumoto, Kana Hayashi, et al.
Molecular and Clinical Oncology|July 15, 2015
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinibMinehiko Inomata, Ryuji Hayashi, Azusa Yamamoto, et al.
Scientific Reports|July 4, 2023
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancerMinehiko Inomata, Masahiro Matsumoto, Naoki Takata, et al.
Endocrine Journal|May 20, 2015
Association of serum adiponectin with asthma and pulmonary function in the Japanese populationYasuko Hayashikawa, Minoru Iwata, Minehiko Inomata, et al.
Translational Lung Cancer Research|December 10, 2025
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301Fumihiko Okumura, Hisashi Tanaka, Katsuhiro Onodera, et al.
Molecular and Clinical Oncology|May 17, 2024
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expressionMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Oncology Reports|April 4, 2012
SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in miceKensuke Suzuki, Ryuji Hayashi, Tomomi Ichikawa, et al.
In Vivo (Athens, Greece)|April 29, 2021
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint InhibitorsKana Hayashi, Kotaro Tokui, Minehiko Inomata, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 31, 2014
Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective studyKensuke Suzuki, Tomomi Ichikawa, Hideaki Furuse, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cancer Diagnosis & Prognosis|May 9, 2022
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung CancerMinehiko Inomata, Masahiro Matsumoto, Isami Mizushima, et al.
Anticancer Research|June 23, 2023
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint InhibitorsMinehiko Inomata, Masahiro Matsumoto, Kana Hayashi, et al.
Molecular and Clinical Oncology|July 15, 2015
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinibMinehiko Inomata, Ryuji Hayashi, Azusa Yamamoto, et al.
Scientific Reports|July 4, 2023
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancerMinehiko Inomata, Masahiro Matsumoto, Naoki Takata, et al.
Endocrine Journal|May 20, 2015
Association of serum adiponectin with asthma and pulmonary function in the Japanese populationYasuko Hayashikawa, Minoru Iwata, Minehiko Inomata, et al.
Translational Lung Cancer Research|December 10, 2025
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301Fumihiko Okumura, Hisashi Tanaka, Katsuhiro Onodera, et al.
Molecular and Clinical Oncology|May 17, 2024
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expressionMinehiko Inomata, Shuhei Minatoyama, Naoki Takata, et al.
Oncology Reports|April 4, 2012
SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in miceKensuke Suzuki, Ryuji Hayashi, Tomomi Ichikawa, et al.
In Vivo (Athens, Greece)|April 29, 2021
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint InhibitorsKana Hayashi, Kotaro Tokui, Minehiko Inomata, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 31, 2014
Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective studyKensuke Suzuki, Tomomi Ichikawa, Hideaki Furuse, et al.
Pageof 7